LIVE WEBINAR: Thursday, February 18, 2021, 5:00 PM – 6:00 PM Eastern Time
What Clinicians Want to Know: Understanding the Factors Affecting the Optimal Diagnosis and Management of Ovarian Cancer
A CME-MOC/NCPD Accredited Virtual Event
Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.
Event Details
5:00 PM – 6:00 PM Eastern Time
Director, Winthrop P Rockefeller Cancer Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kathleen Moore, MD
The Virginia Kerley Cade Endowed Chair in Cancer Development
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
David M O'Malley, MD
Professor
Division Director, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
The Ohio State University and The James Cancer Center
Columbus, Ohio
Moderator
Neil Love, MD
Research To Practice
Miami, Florida
Agenda
Thursday, February 18, 2021
5:00 PM – 6:00 PM Eastern Time
Live CE-accredited webinar
Topics to Be Discussed
- Biology of ovarian cancer (OC); incidence and relevance of various germline and somatic genomic abnormalities
- Indications for and practical implementation of genetic testing for patients with newly diagnosed advanced OC
- Current role of PARP inhibitor maintenance therapy in the first-line setting for patients with advanced OC with and without BRCA mutations
- Identification and management of side effects and other practical considerations with the use of PARP inhibitors in advanced OC
CE Information
Target Audience
This activity is intended for gynecologic oncologists, gynecologists, medical oncologists, medical oncology fellows, nurse practitioners, physician assistants and other healthcare providers involved in the treatment of ovarian cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Assess potential biomarkers of response to PARP inhibition and appraise guideline recommendations and consensus statements regarding the indications for and practical implementation of genetic testing in ovarian cancer (OC), and use the results of these assessments in long-term treatment planning.
- Recognize homologous recombination deficiency as a unique biologic characteristic, understand how it is measured with commercially available assays and consider the clinical implications for patients with OC.
- Evaluate available data with olaparib and with niraparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious germline or somatic BRCA mutation, and counsel appropriate individuals regarding personalized treatment recommendations.
- Consider the current role of niraparib as maintenance therapy in the first-line setting for patients with advanced OC without BRCA mutations, and identify individuals for whom treatment with this strategy may be appropriate.
- Appreciate available clinical trial data with olaparib/bevacizumab as first-line maintenance therapy for patients with newly diagnosed OC responding after first-line platinum/taxane chemotherapy with bevacizumab to determine the role of this novel approach in current clinical practice.
- Compare and contrast the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and understand the supportive management strategies available to minimize or ameliorate these side effects.
Accreditation Statements
Research To Practice (RTP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
RTP is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
RTP designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity. NCPD Credit Designation Statements
This educational activity for 1 contact hour is provided by RTP.
This activity is awarded 1 ANCC pharmacotherapeutic contact hour.
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. The credit form links will be emailed to participants within 5 days of the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.
This activity will be submitted to the ONCC for ILNA verification. AAPA: This program is not yet approved for CME credit. Conference organizers plan to apply for 1 AAPA Category 1 CME credit from the American Academy of Physician Assistants Review Panel. The total number of approved credits is yet to be determined. Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice, the ACCME, ANCC, AANP or AAPA. Any off-label use as declared by the FDA will be identified. Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/NCPD/AANP/AAPA activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Dr Birrer — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: OncoQuest Pharmaceuticals Inc (QPT-ORE-005), VBL Therapeutics (VB-111-701/GOG-3018). Dr Moore — Consulting Agreements: Aravive Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Sorrento Therapeutics, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Contracted Research: PTC Therapeutics, US Department of Defense. Dr O'Malley — Advisory Committee: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genelux, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Myriad Genetic Laboratories Inc, Novocure Inc, Regeneron Pharmaceuticals Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Novocure Inc, Regeneron Pharmaceuticals Inc, Seagen Inc, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, New Mexico Cancer Care Alliance, Novocure Inc, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seagen Inc, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc. Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
Research To Practice CME/NCPD/AANP/AAPA Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.